The pharmaceutical enclosure of the human body has suffered a major blow this week as patents for semaglutide—the active ingredient in Novo Nordisk’s blockbusters Ozempic and Wegovy—expired in India and China. For years, these drugs have been gated behind price points of $200 per month, making them inaccessible to the billions of people in middle-income countries who carry nearly half the world’s obesity burden. Now, Indian manufacturers are set to flood the market with generic versions priced as low as $15 per month.

This is a triumph of the public commons over corporate intellectual property. In India alone, over 50 generic brands are expected to launch this weekend, shattering the monopoly that Novo Nordisk fought desperately to preserve in the courts of Brazil and China. The pharmaceutical giant is now attempting a 'premium' branding strategy to maintain its profit margins, but the tide has turned. Cheaper semaglutide will become a lifeline for nations where obesity and diabetes are rising rapidly, but where the cost of brand-name treatment was a death sentence. By reclaiming the right to produce life-saving medicine, the Global South is asserting that human health is not a luxury commodity.